Objective: Previously, we described risk factors for disease progression in moderate asymptomatic carotid artery stenosis (ASCAS). The aim of the current study was to develop a risk prediction model for disease progression in this group. Methods: All patients presenting between January 2005 and May 2012 with moderate (50%-69%) ASCAS, as determined by carotid artery duplex imaging, were included. Cox proportional hazard regression models accounting for measured duplex peak systolic velocity and end-diastolic velocity, and the internal carotid artery (ICA)/common carotid artery (CCA) ratio, with and without previously identified risk factors for progression (age, smoking, dual antiplatelet therapy), were used to develop receiver operating characteristic curves for predicting disease progression. Results: The study analyzed 282 patients (52% male), aged 71 6 9 years, with 2.6 6 0.1 years follow-up and 25% disease progression at a mean time of 2.02 6 0.18 years. Initial peak systolic velocity, end-diastolic velocity, and the ICA/CCA ratio were all significant independent predictors of progression. Receiver operating characteristic curve analyses suggested that a prediction model based on ICA/CCA ratio alone had optimal prediction efficacy (hazard ratio, 2.01; Harrell's C, 0.74; P < .001). Patients with ICA/CCA >2.5, 3.3, and 3.8 were found to have >10%, >20%, and >30% risk of disease progression over 2 years, respectively. Model sensitivity and specificity for predicting 10% risk of disease progression at 2 years was 80.7% and 64.0%, respectively (positive predictive value, 22.9%; negative predictive value, 96.1%). Conclusions: We propose a clinical prediction model for moderate ASCAS disease progression that can be used to riskstratify patients with >10% risk of progression at 2 years using ICA/CCA ratios. Implementation of this model may be useful for identifying high-risk patients who would benefit from routine carotid disease surveillance follow-up. (J Vasc Surg 2014;60:1585-92.) 
Stroke is associated with a 5-year mortality of 50% to 60% and is the leading cause of disability within the United States and Western Europe. 1 Carotid artery stenosis is thought to account for 10% to 20% of all strokes and can be found in up to 10% of patients, particularly among older patients. 2, 3 The degree of carotid artery stenosis has been found to be the strongest single determinant of stroke risk, with a 60% to 70% reduction in carotid artery luminal diameter associated with a significant increase in risk. 4 Based on level 1 evidence, 5 the European Carotid Surgery Trial, [6] [7] [8] [9] [10] [11] the Society for Vascular Surgery (SVS), 12 and American Heart Association/American Stroke Association have put forth guidelines supporting the use of carotid endarterectomy in symptomatic patients with >50% carotid stenosis who have an estimated perioperative morbidity and mortality risk of <6%, or asymptomatic patients with $60% stenosis and an estimated perioperative morbidity and mortality risk of <3%. 13, 14 However, there are no current guidelines regarding the treatment of patients with an asymptomatic carotid artery stenosis (ASCAS) measuring 50% to 69%. Furthermore, there is no consensus about how often patients who are found to have moderate (50%-69%) ASCAS should be restudied after the initial diagnosis. 12 Some data from >15 years ago suggest that carotid artery duplex measurements (specifically, the peak systolic velocity [PSV] ) can help predict disease progression among patients with <60% ASCAS. 15, 16 However, changes in carotid artery plaque composition and advances in medical management and secondary prevention strategies since that time may have altered previously identified predictive parameters for disease progression. 17 In an effort to address this practice gap, we previously described the rate and clinical risk factors for disease progression among a modern group of patients with moderate ASCAS. 18 We demonstrated that although most patients with moderate ASCAS remained asymptomatic, more than one-quarter of patients would progress to severe disease. Smoking and dual-antiplatelet therapy were independent risk factors for disease progression. The aim of the current study was to develop a risk prediction model for disease progression using carotid artery duplex From 
METHODS
The hospital's Institutional Review Board approved the study. Informed consent was waived because this was a retrospective review.
Study design. We retrospectively reviewed all patients undergoing initial carotid artery duplex between January 2005 and May 2012. Only patients who were asymptomatic at the time of screening and had moderate (50%-69%) carotid artery stenosis on initial carotid artery duplex imaging were included. The study excluded patients with symptoms at the initial visit, those with severe or symptomatic contralateral disease, those who underwent carotid revascularization with carotid endarterectomy or stent #30 days of diagnosis, those with missing carotid duplex measurements at their initial or follow-up study, and those without a repeat carotid duplex follow-up study at least 1 year after their initial study.
The electronic medical records for all included patients were reviewed for information pertaining to patient demographics, comorbidities, smoking status, history of peripheral arterial disease and contralateral carotid artery stenosis, and medication use, including aspirin, anticoagulants, statins, angiotensin-converting enzyme inhibitors, b-blockers, and insulin. PSV, end-diastolic velocity (EDV), and internal carotid artery/common carotid artery (ICA/CCA) ratio measurements from the initial and all subsequent carotid artery duplex studies were recorded. The primary outcome of the study was the progression of moderate (50%-69%) carotid artery stenosis to severe ($70%) stenosis, as noted on the patient's most recent carotid artery duplex findings.
Moderate carotid artery stenosis was defined as a PSV >125 cm/s and <230 cm/s, EDV >40 cm/s and <100 cm/s, and ICA/CCA ratio >2.0 and <4.0 on the carotid artery duplex examination as performed by a registered vascular technologist. All studies were performed in our vascular diagnostic laboratories, which are accredited by the Intersocietal Commission for the Accreditation of Vascular Laboratories.
Statistical methods. Patient demographics and other baseline characteristics are described using mean 6 standard error of the mean or as counts (%), as appropriate. Standard univariable analyses using Student t-tests for continuous variables or Pearson c 2 tests for categoric variables were used to compare baseline characteristics and initial carotid artery duplex measurements (PSV, EDV, ICA/CCA ratio) between patients with moderate ASCAS progression and those without progression.
Multivariable analyses using abbreviated and extended Cox proportional hazard regression models were performed to assess the association between PSV, EDV, and the ICA/ CCA ratio with disease progression. Only the most recent duplex examination for each patient was analyzed. Cox proportional hazards modeling was chosen to account for differences in time between the initial and last follow-up duplex between patients.
Covariates in the extended models were chosen a priori and included age, dual-antiplatelet therapy, smoking, female gender, hypertension, diabetes, hyperlipidemia, coronary artery disease (CAD), kidney disease, statin use, and aspirin use in accordance with the variables used in our initial study. 18 Covariates in the abbreviated models included age, smoking status, and dual-antiplatelet therapy use because results from our previous study demonstrated that smoking and dual-antiplatelet therapy use were independent predictors of moderate ASCAS progression. 18 Smoking was defined for the abbreviated and extended models as "ever-smokers" based on findings from our prior study that there were no significant differences in disease progression between prior smoking and current smoking. 18 Receiver operating characteristic (ROC) curve analyses of each unadjusted and adjusted Cox proportional hazards model were performed to determine the predictive ability of PSV, EDV, and ICA/CCA alone and in combination based on Harrell's C statistics. 19 Harrell's C statistic is analogous to a C statistic (area under an ROC curve) when analyzing longitudinal survival data instead of cross-sectional event data. ROC curve analyses were used to determine the cutoff at which a measure was able to most accurately predict a $10% risk of disease progression to severe stenosis at 2 years. The 10% risk probability was chosen based on perceived clinical effect and the previously reported observation that disease progression in patients with ASCAS followed a linear trend, including 7.6% progression at 1 year, 17.6% progression at 2 years, and 25.1% progression overall. 18 The 2-year period was chosen based on mean time to disease progression within the study cohort and the observation of a significant degradation in model accuracy outside of 2 years.
Prediction model reliability was validated using subgroup analyses and split-sample training. For the latter, a random training set and test set were generated using data from within the same study cohort, and Harrell's C statistics for the full cohort vs test cohort were compared to assess reliability of the predictive model. 19 Stata 12 software (StataCorp LP, College Station, Tex) was used for all analyses. All P -values are two-tailed and considered significant at P # .05.
RESULTS
Cohort characteristics. Overall, 282 patients with carotid duplex imaging velocities were analyzed. The mean age at the first duplex examination was 70.6 6 0.55 years, 147 patients (52.1%) were male, and 246 (87.2%) were white. The mean follow-up time was 2.6 6 0.10 years. Disease progression from moderate ASCAS to severe carotid artery stenosis occurred in 71 patients (25.2%) at a mean time of 2.02 6 0.18 years.
Baseline comorbidities and demographic characteristics were similar in patients who experienced carotid artery disease progression compared with those who did not, with the exception of dual-antiplatelet therapy use. As previously reported, more patients with disease progression were using dual-antiplatelet therapy compared with those without progression (40.9% vs 27.7%; P ¼ .04; Table I ). Baseline carotid duplex measurements, including PSV, EDV, and the ICA/CCA ratio, were all significantly higher in patients with progression compared with those with stable disease (Table II) .
Association between initial carotid duplex measurements and disease progression. We previously demonstrated that the adjusted risk of ASCAS progression in this patient cohort was higher in patients receiving dualantiplatelet therapy (hazard ratio [HR], 1.87; 95% confidence interval [CI], 1.10-3.16; P ¼ .02) and in eversmokers (HR, 1.91; 95% CI, 0.99-3.64; P ¼ .05). Age, female gender, hypertension, diabetes, hyperlipidemia, CAD, kidney disease, statin use, and aspirin use were not significant predictors of progression from moderate to severe stenosis. 18 In the present study, we evaluated the association between carotid duplex measurements and disease progression. Univariable analysis showed that initial PSV, EDV, and ICA/CCA ratio measurements were all significantly associated with significantly increased HRs of disease progression (P < .0001; Table III ). Multivariable Cox regression analysis correcting for age, use of dual antiplatelet therapy, and smoking, found that the initial PSV, EDV, and the ICA/CCA ratio remained independent predictors of disease progression (P < .0001; Table III) . Results of multivariable Cox regression correcting for all previously explored model covariates (age, dual antiplatelet therapy, smoking, female gender, hypertension, diabetes, hyperlipidemia, CAD, kidney disease, statin use, and aspirin use) were consistent with these findings, with PSV, EDV, and the ICA/CCA ratio remaining independent predictors of progression after risk adjustment (P < .0001; data not shown).
Prediction model derivation. ROC curve analyses of Cox regression models containing each of the three baseline carotid duplex measures separately and together are reported in Table III . Each of the unadjusted models was significantly predictive of disease progression (Harrell's C, 0.69-0.77; all P < .0001). After adjusting for age, dualantiplatelet use, and smoking, the models were similarly predictive of progression (Harrell's C, 0.72-0.78; all P < .0001). Harrell's C was similar comparing the unadjusted vs adjusted versions for each of the seven prediction models that we tested (all P ¼ NS; Table III ), suggesting that the addition of age, dual-antiplatelet use, and smoking as model covariates had no significant effect on model discrimination.
Based on these findings, we investigated the utility of the simplest possible model to predict disease progression. The ICA/CCA ratio was the strongest independent predictor for disease progression on univariable (HR, 2.01; P < .0001) and multivariable (HR, 1.90; P < .0001) analysis (Table III) , with an unadjusted Harrell's C of 0.74 (Fig 1, A) . Using ROC curve analyses, we found that the ICA/CCA ratio optimally predicted ASCAS disease progression with a probability cutoff of 0.10 (Fig 1, B) . Assuming this $10% risk of progression as a positive test, a cutoff ICA/CCA ratio of 2.5 was able to predict 2-year ASCAS progression with a sensitivity of 80.7% and a specificity of 64.0%. The positive and negative predictive values of ICA/CCA >2.5 for predicting progression were 22.9% and 96.1%, respectively. Overall, a ICA/CCA ratio cutoff of 2.5 correctly classified 2-year ASCAS progression in 65.9% of patients. Further analyses identified ICA/CCA ratios of >3.3 and >3.8 as the cutoff at which this measure optimally predicted progression risks of $20% and $ 30% at 2 years, respectively (Table IV) .
Validation of the ICA/CCA ratio as a clinical prediction tool. To assess the reliability of using only the ICA/CCA ratio to predict ASCAS disease progression, we performed subgroup analyses to assess model discrimination within a variety of different patient cohorts. The ICA/CCA Harrell's C was similar comparing older ($65 years) vs younger (<65 years) patients, smokers (ever-smoker, prior smokers, and current smokers) vs nonsmokers, and patients with vs without dual-antiplatelet therapy (all P ¼ NS; Table V ). There were also no significant differences in the ICA/CCA Harrell's C comparing surgical location (main vs ancillary hospital), patient gender, aspirin use, statin use, or major comorbidities (all P ¼ NS; Table V) .
To validate the use of the ICA/CCA ratio to predict ASCAS progression, we performed a split-sample training and test run on a randomly generated portion of our original cohort (50% in each group). Within the training sample, the ICA/CCA ratio was associated with disease progression with a HR of 2.08 (95% CI, 1.55-2.79). The results from the model using the training sample were then applied to the test sample and were able to predict ASCAS progression to severe stenosis with a Harrell's C of 0.72 (95% CI, 0.63-0.80), which was not significantly different from the original Harrell's C of 0.74 (95% CI, 0.68-0.81) generated using the full derivation cohort.
DISCUSSION
The appropriate management of patients with asymptomatic moderate (50%-69%) carotid artery stenoses is unclear. 11, 20 Furthermore, the appropriateness of postdiagnosis surveillance for progression of carotid disease among patients without symptoms is unknown. 3 Existing guidelines do not endorse routine surveillance with duplex ultrasound imaging for progression of moderate (50%-69%) ASCAS on the assumption that the overall risk of stroke is low in patients without pre-existing evidence of cerebral ischemia. 3, 13, 14, 21 However, our data and other data on this topic [22] [23] [24] [25] [26] [27] [28] [29] [30] suggest that patients with identifiable risk factors for carotid artery disease progression may warrant more careful follow-up.
We previously demonstrated that among a cohort of 258 asymptomatic patients with moderate ASCAS, >25% of patients will have disease progression to severe ($70% stenosis) by a mean time of 2 years. In the current study, we used the same patient cohort to evaluate the predictive efficacy of carotid duplex measurements for identifying patients with moderate ASCAS who are at increased risk for disease progression. Using multivariable modeling and ROC curve analyses, we found that an ICA/CCA ratio >2.5 on the initial screening duplex was the most accurate predictor of disease progression in this group. Furthermore, the predictive efficacy of the model was largely unchanged with the addition of other clinical factors, making the ICA/CCA ratio a simple, clinically applicable means by which physicians could potentially identify high-risk patients.
Based on the findings of this study, we suggest that routine surveillance follow-up with carotid duplex imaging could be targeted to certain patients at high risk for disease progression based on their initial ICA/CCA ratio, thereby maximizing screening efficacy to identify and prevent strokes in high-risk patients with moderate ASCAS in a costeffective manner. We propose such an algorithm in the moderate ASCAS decision-making tree presented in Fig 2. The precise times at which postdiagnosis surveillance imaging should be performed are unclear. We previously reported a 7.6% incidence of moderate ASCAS progression at 1 year, 17.6% at 2 years, and 35.9% at 4 years. 18 On the basis of these observations, combined with the fact that the carotid progression risk prediction model we present here was constructed around a 2-year risk of progression, we would recommend 1-year surveillance intervals for patients with an ICA/CCA ratio >2.5. This approach may be slightly more frequent than needed, but the risks associated with duplex imaging are low compared with the potential morbidity and mortality that is associated with stroke. 31 Patients who meet criteria for 20% and 30% risk of progression (ie, ICA/CCA ratio >3.3 and 3.8, respectively) would likely benefit from more frequent surveillance (eg, every 3 or 6 months), although the optimal interval is unclear from the available data, and insurer buy-in would be required to implement this approach. The senior author (M.B.M.) recently included this enhanced screening in his practice, and to our knowledge, has not encountered an issue with insurance coverage to date. It is possible that patients with other risk factors, such as smoking and dual-antiplatelet use, would also benefit from more frequent surveillance, although the data in our cohort did not demonstrate a clear benefit in predictive efficacy by adding clinical factors into the model. Use of the internal carotid artery (ICA)/common carotid artery (CCA) ratio for predicting asymptomatic carotid artery stenosis (ASCAS) progression. A, Receiver operating characteristic (ROC) curve analyses suggested that the ICA/CCA ratio at initial presentation alone could predict progression of ASCAS to severe carotid artery stenosis with the simplest maximum efficacy (Harrell's C, 0.74). B, Assuming a $10% risk of progression as a positive test, a ICA/CCA ratio cutoff of 2.5 was able to predict 2-year ASCAS progression with a sensitivity of 80.7% and specificity of 64.0%. Of note, the negative predictive value of 96.1% of our prediction model suggests a risk of disease progression of <5% in patients with an ICA/CCA ratio of #2.5. We would argue that patients who fall below this threshold can likely be discharged from regular surveillance unless their clinical picture changes, in accordance with the previously mentioned American Society of Neuroimaging guidelines that quote a lack of cost-effectiveness and potential for harm among patients with an assumed disease prevalence of <5%.
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Our finding that the ICA/CCA ratio was the best predictor of disease progression is novel. Current consensus criteria use ICA PSV thresholds of $125 cm/s and $230 cm/s for diagnosing $50% and $70% carotid artery stenosis, respectively. 12 These guidelines are based on recommendations made by the Society of Radiologists in Ultrasound, who met in 2002 to publish formal criteria for the diagnosis of carotid artery stenosis using duplex ultrasound imaging based on a combination of published data and expert opinion. 33 Since that time, AbuRahma et al 34 have lauded the accuracy of PSV over EDV and the ICA/CCA ratio for diagnosing carotid artery stenosis. Using angiography as the gold standard, they quote an overall accuracy of 85% using PSV for diagnosing carotid artery stenosis $50% vs 81% with the ICA/ CCA ratio. Our study found that PSV, EDV, and the ICA/CCA ratio were all independent predictors of ASCAS progression. However, based on a notably higher HR of 2.01 for progression with an ICA/CCA ratio and a corresponding Harrell's C of 0.74, we chose to use this measurement in our clinical prediction model over PSV or EDV, which had similar Harrell's C values but notably lower HRs. Although PSV is a commonly reported measure among historical reports of ASCAS progression, 15, 16 the ICA/ CCA ratio is infrequently studied. On the basis of prior findings that the ICA/CCA ratio tends to overdiagnose carotid disease compared with PSV, 34 we predict that the ICA/CCA ratio may have increased sensitivity for subtle changes in carotid velocities that are lost with other measures. Although velocities can increase due to several physiologic factors, the ICA/CCA ratio may be a more accurate predictor of local disease progression.
A model that has a tendency to overpredict disease progression is preferable to one that underpredicts progression when it is to be used for screening purposes, because screening too many patients poses less clinical risk than screening too few, particularly when stroke is the outcome one is trying to prevent. Of note, our finding that an ICA/CCA ratio >2.5 has a sensitivity of 80.7% for predicting disease progression is remarkably similar to the 81% sensitivity that was reported by AbuRahma et al, 34 albeit our study focuses on the utility of carotid duplex measurements for predicting disease progression rather than for making an initial diagnosis of carotid artery stenosis. Also similar to the findings by AbuRahma et al, 34 we found no additive benefit to combining multiple duplex measurements in our model.
The limitations of our study deserve discussion. The study design was a retrospective review of data abstracted from the electronic medical records, which carries a standard risk of missing or inaccurate data recording that cannot be rectified. We attempted to limit any bias the study design might carry by limiting our analysis to patients with at least 1 year of follow-up. In addition, all clinical prediction models were calculated from carotid duplex studies performed by a fully accredited laboratory technician and interpreted by board-certified vascular surgeons who had no knowledge of the patients' clinical details.
Another limitation to our study is that there is no currently available database with which we can validate our ICA/CCA prediction model; to date, our study is the largest that we know of to report the natural history of disease progression among patients with moderate (50%-69%) ASCAS, so finding a second population to test our ICA/CCA ratio cutoffs is not currently feasible. We performed subgroup analyses and split-sample training within the patients in our cohort in an attempt to show reliability of the model and found no differences in predictive efficacy of the ICA/CCA ratio cutoffs that we identified, regardless of patients' clinical characteristics or previously recognized risk factors for atherosclerotic disease. However, future studies assessing the cost-effectiveness of our proposed surveillance algorithm or similar approaches for monitoring patients with moderate ASCAS are needed to allow for prospective validation of our model.
CONCLUSIONS
Our data suggest that patients with ASCAS and an ICA/CCA ratio >2.5 may warrant routine surveillance for carotid artery disease progression beyond an initial ultrasound study. We propose an algorithm for the surveillance of high-risk patients that we hope will allow for maximal predictive ability in a cost-effective manner and that could potentially be applied in a prospective fashion to aid in the early diagnosis and intervention of patients at high risk for progression of moderate to severe carotid artery stenosis. 
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